metformin has been researched along with aspalathin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dludla, P; February, F; Ghoor, S; Johnson, R; Joubert, E; Louw, J; Mazibuko, S; Muller, C | 1 |
| Dludla, PV; Gabuza, KB; Johnson, R; Joubert, E; Louw, J; Muller, CJF | 1 |
| Chellan, N; Cirilli, I; Dludla, PV; Essop, MF; Ghoor, S; Huisamen, B; Johnson, R; Louw, J; Marcheggiani, F; Mazibuko-Mbeje, SE; Muller, CJF; Nkambule, BB; Orlando, P; Silvestri, S; Tiano, L | 1 |
3 other study(ies) available for metformin and aspalathin
| Article | Year |
|---|---|
Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference and apoptosis.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cells, Cultured; Chalcones; Drug Therapy, Combination; Glucose; Glutathione; Membrane Potential, Mitochondrial; Metformin; Myocytes, Cardiac; Oxidative Stress; Protective Agents; Rats; Reactive Oxygen Species; Superoxide Dismutase | 2016 |
Aspalathin, a C-glucosyl dihydrochalcone from rooibos improves the hypoglycemic potential of metformin in type 2 diabetic (db/db) mice.
Topics: Animals; Aspalathus; Chalcones; Diabetes Mellitus, Type 2; Drug Synergism; Flavonoids; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Transgenic | 2018 |
The Combination Effect of Aspalathin and Phenylpyruvic Acid-2-
Topics: AMP-Activated Protein Kinase Kinases; Animals; Aspalathus; Cells, Cultured; Chalcones; DNA Damage; Energy Metabolism; Gene Expression; Glucose; Glucosides; Membrane Potential, Mitochondrial; Metformin; Myocytes, Cardiac; NADPH Oxidases; Oxidative Stress; Phenylpyruvic Acids; PPAR alpha; Protein Kinases; Rats; Reactive Oxygen Species | 2020 |